HIV-1 reverse transcriptase inhibitors remain a cornerstone of antiretroviral therapy, targeting the enzyme responsible for converting viral RNA into DNA. This class of drugs, particularly nucleoside ...
Brown researchers will look into how a drug originally developed to treat HIV may reduce age-related inflammation.
The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...
The inhibition of HIV-1’s replicative machinery remains a cornerstone in the battle against AIDS. Central to this approach are inhibitors targeting reverse transcriptase (RT) and integrase. Reverse ...
The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ROME Therapeutics, a biotechnology company harnessing the power of the dark genome for drug development, today announced a new publication in The Proceedings of the ...
The World Health Organization recommends dolutegravir with two nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Many cancers exhibit high levels of the reverse transcriptase enzyme. Single-agent lamivudine, a reverse transcriptase inhibitor, stopped disease progression in over 25% of patients with fourth-line ...
MedPage Today on MSN
Novel Two-Drug Combo Equals Standard Triplet in Untreated Patients With HIV
The doravirine and islatravir pair could offer an alternative to INSTI-based treatment opt ...
At the 2026 Conference on Retroviruses and Opportunistic Infections, Gilead and Merck demonstrated that their respective daily oral HIV drugs can match current therapies in keeping the virus at bay.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results